NEXTRACKER
14.3.2023 07:04:42 CET | Business Wire | Press release
Nextracker Inc. (NASDAQ: NXT) secured a new deal in Europe for its terrain-following solar tracker NX Horizon-XTR™ (XTR), demonstrating demand for tracking technology that enables solar developers to build on land with complex topography and unique environmental constraints. The German international solar developer, IbVogt, chose Nextracker’s XTR for the 150 MW Garnacha solar power plant in Spain. The project is backed by a 12-year power purchase agreement (PPA) with Google and is expected to begin production October of 2023. Leading the global market in solar trackers and optimization software, Nextracker’s advanced technology systems allow solar panels to follow the sun’s movement and maximize energy output.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005879/en/
European Renewable Energy Developer IbVogt chooses Nextracker’s NX Horizon-XTR for its upcoming 150 MW project in Spain (Photo: Business Wire)
“Due to the local zero grading requirements on our project, we needed a solar tracker solution that would have minimal environmental impact and allow us to secure local permits,“ stated Patrick Zenker, Global Procurement Director of IbVogt. ” With a 10-gigawatt track record, NX Horizon-XTR gave us peace of mind and low risk."
“With gas price volatility, European leaders are looking for the lowest cost, most reliable form of energy, and that is utility scale solar power,” said Dan Shugar, Founder and CEO of Nextracker. “Europe’s exceptional environmental stewardship, unique cultural sites and challenging topography provide the perfect conditions for our terrain-following trackers that maximize energy output with a light-on-land footprint.”
Nextracker’s NX Horizon-XTR™ allows rows of solar panels to adjust to uneven terrain, following the natural curvature of the earth. Its terrain-following capabilities enable developers to work on challenging sites that would otherwise be infeasible. It also cuts costs by limiting grading work and associated delays, simplifying the permitting process, and reducing the need for soil-related maintenance.
Solar projects using NX Horizon-XTR have a lighter impact on the environment as they leave more soil intact, benefitting the local ecology and reducing risk of soil erosion. The projects also require less steel for extended pilings, lowering a project’s overall carbon footprint.
The Garnacha project expands Nextracker’s multi-gigawatt portfolio in Europe. The company has offices in Seville and Madrid, with dedicated employees working with customers across the continent with deep expertise to support the life cycle of every project.
“The Nextracker European team has achieved an important milestone of reaching over 3 GW of projects with major solar developers, utilities and European EPC companies for projects in Europe as well as Brazil, USA, Canada and Africa,” said Arturo Herrero, Nextracker SVP Europe.
Nextracker, a leading solar tracking company with 70 GW shipped globally to five continents, has deployed their terrain-following NX-Horizon XTR on close to 10 GW of utility-scale solar globally. Nextracker’s solar trackers increase energy production by 20-30% more than fixed-tilt applications that do not track the sun.
About Nextracker
Nextracker is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and ground-mounted distributed generation solar projects around the world. Our products enable solar panels in utility-scale power plants to follow the sun’s movement across the sky and optimize plant performance. With more than 70 gigawatts shipped worldwide, Nextracker offers solar tracker technologies that optimize and increase energy production while reducing costs for significant plant ROI. For more information, please visit Nextracker.
Stay in touch with us: Twitter LinkedIn Instagram Facebook
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom